Medicalchain

May 16, 2018

The information set forth below may not be exhaustive and does not imply any elements of a contractual relationship. While we make every effort to ensure that any material in this whitepaper is accurate and up to date, such as products, services, technical architecture, token distribution, company timelines - such material could be subject to change without notice and in no way constitutes a binding agreement or the provision of professional advice.

Spotlight

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology. Our lead drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis (SK), a common non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

OTHER WHITEPAPERS
news image

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Read More
news image

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More
news image

BUILDING RESILIENT SUPPLY CHAINS REVITALIZING AMERICAN MANUFACTURING AND FOSTERING BROAD-BASED GROWTH

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.

Read More
news image

Expediting early-phasedevelopment ofsmall molecules: Anintegrated approach

whitePaper | November 18, 2022

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).

Read More
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More
news image

The convergence of the pharmaceutical and medicaldevices industries

whitePaper | May 26, 2022

The medical device and pharmaceutical industries each share in a mission to improve health outcomes, from prevention to intervention. As a result of this shared mission, integration and overlap between these two industries has been taking place for decades.

Read More

Spotlight

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology. Our lead drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis (SK), a common non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

Events